The changes observed during flight on the whole corresponded with the preflight prognosis and reflected the phase nature of the processes of adaptation. They were shown by blood redistribution symptoms, fluctuations in the main indices of hemodynamics at rest not going beyond the limits of the physiological norm, an increase in the pulse-filling of the head with blood, and a decrease in that of the shank. The reaction of the blood circulation to a physical load and the application of negative pressure varied, and in a number of investigations during flight it was more pronounced than on Earth. The changes observed after the flight appeared regular for the period of readaptation of the reactions of the organism. These reactions bore a functional nature and qualitatively did not differ from reactions observed after other flights, and after the 140-day flight they were, on the whole, less pronounced than after the 96-day flight. In the postflight period to accelerate the process of adaptation a complex of restorative-healing measures was carried out, including mainly a regulation of motor activity, restorative massage of the muscles, remedial physical culture and aquatic procedures. The flight lasting 140 days revealed no contraindications to a further regular increase in the time of cosmic flights and demonstrates once again the possibility of the planned control of the state of a healthy subject in flight and the readiness of the organism for a return to the terrestrial force of gravity.

Download full-text PDF

Source

Publication Analysis

Top Keywords

changes observed
8
observed flight
8
flight pronounced
8
flight
7
preliminary medical
4
medical investigations
4
investigations piloted
4
piloted flights
4
flights salyut-6
4
salyut-6 program
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Suven Life Sciences, Hyderabad, Telangana, India.

Background: Alzheimer's disease (AD) agitation is a distressing neuropsychiatric symptom characterized by excessive motor activity, verbal aggression, or physical aggression. Agitation is one of the causes of caregiver distress, increased morbidity and mortality, and early institutionalization in patients with AD. Current medications used for the management of agitation have modest efficacy and have substantial side effects.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Biogen, Cambridge, MA, USA.

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the formation of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) composed of tau aggregates. Research in animal models has generated hypotheses on the underlying mechanisms of the interaction between Aβ and tau pathology. In support of this interaction, results from clinical trials have shown that treatment with anti-Aβ monoclonal antibodies (mAbs) affects tau pathology.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Signant Health, Blue Bell, PA, USA.

Background: In Alzheimer's Disease trials, the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR) are commonly utilized as inclusionary criteria at screening. These measures, however, do not always reaffirm inclusionary status at baseline. Score changes between screening and baseline visits may imply potential score inflation at screening leading to inappropriate participant enrollment.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Cognition Therapeutics, Purchase, NY, USA.

Background: CT1812 is an experimental therapeutic sigma-2 receptor modulator in development for Alzheimer's disease (AD) and dementia with Lewy bodies. CT1812 reduces the affinity of Aβ oligomers to bind to neurons and exert synaptotoxic effects. This phase 2, multi-center, international, randomized, double-blind, placebo-controlled trial assessed safety, tolerability and effects of CT1812 on cognitive function in individuals with AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Department of Bioengineering, University of California, Los Angeles, CA, USA, Los Angeles, CA, USA.

Background: The initiation of amyloid plaque deposition signifies a crucial stage in Alzheimer's disease (AD) progression, which often coincides with the disruption of neural circuits and cognitive decline. While the role of excitatory-inhibitory balance is increasingly recognized in AD pathophysiology, targeted therapies to modulate this balance remain underexplored. This study investigates the effect of perampanel, a selective non-competitive AMPA receptor antagonist, in modulating neurophysiological changes in hAPP-J20 transgenic Alzheimer's mice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!